TargetBeta
ATR
ATR checkpoint kinase · also FRP1, SCKL, SCKL1, MEC1 · Armadillo like helical domain containing
3 programs in company-led studies act on ATR, from 3 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ceralasertibrule | AstraZeneca | phase 3 | 167 running | – | NCIt |
| TCC1727 | Sino Biopharmaceutical | phase 2 | 22 running | – | the company's pipeline |
| FXS887rule | Fosun Pharma | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 program
- Melanoma, 1 program
- Neoplasms, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 28, 2027FXS887 · Fosun Pharma · phase 1 · NCT07345637
- Sep 30, 2028TCC1727 · Sino Biopharmaceutical · phase 2 · NCT07371663
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.